Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced the poster presentation at the 53rd Child Neurology Society (CNS) Annual Meeting of safety data from its prior Phase 3 ATTeST (Ataxia-Telangiectasia Trial with the EryDex SysTem; #IEDAT-02-2015/NCT02770807) clinical trial. The objective of the data analysis was to evaluate treatment-emergent adverse events (TEAEs) in patients with Ataxia-Telangiectasia (A-T) treated with the company’s lead asset, EryDex (intra-erythrocyte dexamethasone sodium phosphate), for one year compared to placebo control.

Key findings reported in the poster presentation, titled Treatment-Emergent Adverse Events (TEAEs) in Children With Ataxia-Telangiectasia Treated for One Year With Intra-Erythrocyte Dexamethasone Sodium Phosphate (EryDex), include:

  • EryDex treatment was generally well tolerated with most TEAEs being mild to moderate and transient, and generally similar between EryDex- and placebo-treated patients.
  • Side effects typically attributed to chronic steroid use, such as Cushingoid features, hyperglycemia, hirsutism, or hypertension, were not observed.
  • Three patients were discontinued from the study: one patient in the low-dose group had a serious adverse event (SAE) of B-cell lymphoma (unlikely treatment related) and two patients in the high-dose group had TEAEs of pyrexia and tachycardia (one patient, probably treatment related) and pain and pruritus (one patient, possibly treatment related).
  • There were no TEAEs leading to death.

Dirk Thye, M.D., Quince’s Chief Executive Officer and Chief Medical Officer, said, “Results from the ATTeST study, including the emerging safety profile of intra-erythrocyte dexamethasone treatment, suggest that EryDex may be a promising therapy for patients with A-T and should be further evaluated for potential investigational treatment for patients requiring chronic steroid use. We are pleased to advance EryDex treatment in our pivotal Phase 3 NEAT study, currently enrolling patients with A-T in the U.S. and in Europe, with topline results expected in the fourth quarter of 2025.”

Pivotal Phase 3 NEAT Clinical Trial

Quince is currently enrolling a pivotal Phase 3 NEAT (Neurologic Effects of EryDex on Subjects with A-T; #IEDAT-04-2022/NCT06193200) clinical trial, which is an international, multi-center, randomized, double-blind, placebo-controlled clinical trial evaluating the neurological effects of EryDex treatment in patients with A-T. The company plans to enroll approximately 86 patients with A-T ages six to nine years old (primary analysis population) and approximately 20 patients with A-T ages 10 years or older.

The Phase 3 NEAT trial is being conducted under a Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA), and the company expects to report topline results in the fourth quarter of 2025 with a potential New Drug Application (NDA) submission to the FDA and a Marketing Authorization Application (MAA) submission to the European Medicines Agency (EMA) in 2026, assuming positive study results. Additionally, Quince was granted Fast Track designation by the FDA for the company’s EryDex System for the treatment of patients with A-T based on the potential for EryDex to address a high unmet medical need in A-T.

About Ataxia-Telangiectasia

A-T is an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in the ATM gene, which is responsible for cell homeostatic and cell division functions including but not limited to double-stranded DNA repair. Typically, A-T is first diagnosed before the age of five as children begin to develop an altered gait and fall with greater frequency. Neurological symptoms worsen and patients with A-T frequently become wheelchair-bound by adolescence. Teenage years for patients with A-T are typically marked by repeated infections, pulmonary impairment, and malignancies. The median lifespan is approximately 25 to 30 years old with mortality due to infections and malignancy. Based on IQVIA Medical Claims (Dx), PharmetricsPlus (P+), and IQVIA Analytics information, there are approximately 4,600 diagnosed patients with A-T in the U.S. Quince estimates that there are approximately 5,000 patients with A-T in the U.K. and EU4 countries. There are currently no approved therapeutic treatments in any global market for A-T.

About EryDex for A-T

The EryDex System is a drug/device combination product comprised of dexamethasone sodium phosphate (DSP) which is encapsulated and administered using a patient’s own red blood cells (autologous erythrocytes). DSP is a corticosteroid well known for its anti-inflammatory properties as well as its dose-limiting toxicity due to adrenal suppression. The EryDex System is designed to provide the efficacy of corticosteroids and to reduce or eliminate the significant adverse effects that accompany chronic use of corticosteroid treatment.

EryDex leverages Quince’s proprietary Autologous Intracellular Drug Encapsulation (AIDE) technology platform that uses an automated process designed to encapsulate and administer a drug using the patient’s own red blood cells. Red blood cells have several characteristics that make them a potentially effective vehicle for drug delivery, including potentially better tolerability, enhanced tissue distribution, reduced immunogenicity, and prolongation of circulating half-life. Quince’s AIDE technology is designed to harness these benefits to allow for the chronic administration of drugs that have limitations due to toxicity, poor biodistribution, suboptimal pharmacokinetics, or immune response.

About Quince Therapeutics

Quince Therapeutics (Nasdaq: QNCX) is a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases. For more information on the company and its latest news, visit www.quincetx.com and follow Quince Therapeutics on social media platforms LinkedIn, Facebook, X, and YouTube.

Forward-looking Statements

Statements in this news release contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. All statements, other than statements of historical facts, may be forward-looking statements. Forward-looking statements contained in this news release may be identified by the use of words such as “believe,” “may,” “should,” “expect,” “anticipate,” “plan,” “believe,” “estimated,” “potential,” “intend,” “will,” “can,” “seek,” or other similar words. Examples of forward-looking statements include, among others, statements relating to current and future clinical development of EryDex, including for the potential treatment of Ataxia-Telangiectasia (A-T) and other potential indications, related development and commercial-stage inflection point for EryDex, the company’s proprietary Autologous Intracellular Drug Encapsulation (AIDE) technology for treatment of other rare diseases; the strategic development path for EryDex; planned regulatory agency submissions and clinical trials and timeline, prospects, and milestone expectations; the timing and success of the clinical trials and related data, including plans and the ability to initiate, fund, enroll, conduct, and/or complete current and additional studies; the company’s future development plans and related timing; the company’s focus, objectives, plans, and strategies; and the potential benefits of EryDex, AIDE technology and the company’s market opportunity. Forward-looking statements are based on Quince’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict and could cause actual results to differ materially from what the company expects. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, but are not limited to, the risks and uncertainties described in the section titled “Risk Factors” in the company’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on August 13, 2024, and other reports as filed with the SEC. Forward-looking statements contained in this news release are made as of this date, and Quince undertakes no duty to update such information except as required under applicable law.

Media & Investor Contact: Stacy Roughan Quince Therapeutics, Inc. Vice President, Corporate Communications & Investor Relations ir@quincetx.com

Quince Therapeutics (NASDAQ:QNCX)
과거 데이터 주식 차트
부터 11월(11) 2024 으로 12월(12) 2024 Quince Therapeutics 차트를 더 보려면 여기를 클릭.
Quince Therapeutics (NASDAQ:QNCX)
과거 데이터 주식 차트
부터 12월(12) 2023 으로 12월(12) 2024 Quince Therapeutics 차트를 더 보려면 여기를 클릭.